Related Experiment Video
Updated: Jun 6, 2026
Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells
Published on: August 17, 2022
Are autoantibodies against the beta1-adrenergic receptor markers for dilated cardiomyopathy?
Ragna Arndt-Marić1, Herbert Nägele, Gabriele Schewe
1Labor Lademannbogen, Hamburg, Germany.
Insights
Autoantibodies against the beta1-adrenergic receptor (beta1-AR) are present in heart failure patients, indicating a potential autoimmune cause for dilated cardiomyopathy (DCM). These findings suggest beta1-AR autoantibodies may aid in diagnosing and understanding DCM.
Area of Science:
- Cardiology
- Immunology
- Heart Failure Research
Background:
- Dilated cardiomyopathy (DCM) is a major cause of heart failure with no specific early diagnostic markers.
- Autoimmune reactions, particularly targeting the beta1-adrenergic receptor (beta1-AR), are implicated in DCM pathogenesis.
- Current diagnostic approaches lack specificity for identifying autoimmune-related heart conditions.
Purpose of the Study:
- To investigate the presence and significance of autoantibodies against the beta1-AR in patients with heart failure.
- To determine if beta1-AR autoantibodies can serve as a diagnostic marker for autoimmune DCM.
- To explore the clinical characteristics of heart failure patients with and without beta1-AR autoantibodies.
Main Methods:
- Generated a recombinant GST-beta1-AR fusion protein for autoantibody detection.
- Analyzed sera from 115 heart failure patients (DCM, NISCM, CAD) and controls for beta1-AR autoantibodies.
- Correlated antibody presence with patient age, ejection fraction (EF), and NT-proBNP levels.
Main Results:
- Autoantibodies against beta1-AR were detected in 37% of DCM, 30% of NISCM, and 36% of CAD patients.
- Antibody-positive patients were generally younger and had lower ejection fraction (EF) levels.
- Surprisingly, antibody-positive patients exhibited lower NT-proBNP levels compared to antibody-negative counterparts.
Conclusions:
- Detection of beta1-AR autoantibodies can help characterize and differentiate DCM patients, suggesting autoimmune involvement.
- Autoimmune DCM patients tend to be younger, potentially indicating an early disease stage or specific trigger.
- The observed lower NT-proBNP levels in antibody-positive patients despite worse clinical manifestations warrant further investigation into the antibodies' impact.
Background:
Dilated cardiomyopathy (DCM) is one of the leading causes of heart failure in the western world but there is still no specific and early diagnosis available. Besides a genetic predisposition and viral infections, autoimmune reactions play an important role in the pathogenesis of DCM. The beta1-adrenergic receptor (beta1-AR) has been described as the major target structure in autoimmune DCM.
Methods:
In this study a recombinant GST-beta1-AR fusion protein comprising the second extracellular loop was generated as a target for the analysis of autoantibodies in sera from 115 patients with different heart failure diseases (41 DCM, 30 non-ischemic secondary cardiomyopathy [NISCM], 44 coronary artery disease [CAD]). Sera were collected from a non-selected population of heart failure patients in consecutive order.
Results:
Autoantibodies against the beta1-AR were detected in 37% of DCM, 30% of NISCM, and 36% of CAD patients but none of the controls were positive. Furthermore, our data show that cardiomyopathy patients with anti-beta1-AR antibodies are younger (54 years vs. 61 years [DCM], 53 years vs. 56 years [NISCM], 61 years vs. 61 years [CAD]. Regardless of diagnosis antibody-positive patients had lower EF levels (29% vs. 32%, p = 0.0001 [DCM]; 23% vs. 25%, p < 0.0001 [NISCM]; 23% vs. 25%, p < 0.0001 [CAD]) than the antibody-negative counterparts but, nevertheless, also lower NT-proBNP levels compared to antibody negative patients (567 pg/mL vs. 1296 pg/mL, p = 0.0005 [DCM]; 224 pg/mL vs. 1135 pg/mL, p = 0.0002 [NISCM]; 605 pg/mL vs. 940 pg/mL, p = 0.0005 [CAD]).
Conclusions:
We conclude that DCM patients should be further characterized and differentiated by the detection of autoantibodies against beta1-AR. Autoimmune DCM patients are younger compared with their non-autoimmune counterparts, possibly due to the autoimmune trigger of the disease or reflecting an early stage of the disease. Surprisingly, the autoimmune patients have worse clinical manifestations but show less excessive NT-proBNP levels. It is not clear yet, though, whether these autoantibodies have a direct impact on the NT-proBNP levels. Whether or not these data are a consequence of pathogenic antibodies has to be elucidated in further studies.
Related Concept Videos
01:30Cardiomyopathy II: Dilated Cardiomyopathy
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:25Cardiomyopathy I: Introduction and Classification
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers